Page 1796 - Williams Hematology ( PDFDrive )

1770 Part XI: Malignant Lymphoid Diseases Chapter 107: Myeloma 1771

559. Ghobrial IM, Rajkumar SV: Management of thalidomide toxicity. J Support Oncol 592. Facon T, Avet-Loiseau H, Guillerm G, et al: Chromosome 13 abnormalities identified
1:194–205, 2003. by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging
560. Bastuji-Garin S, Ochonisky S, Bouche P, et al: Incidence and risk factors for thalido- system for patients receiving high-dose therapy. Blood 97:1566–1571, 2001.
mide neuropathy: A prospective study of 135 dermatologic patients. J Invest Dermatol 593. Berenson JR, Jagannath S, Barlogie B, et al: Safety of prolonged therapy with borte-
119:1020–1026, 2002. zomib in relapsed or refractory multiple myeloma. Cancer 104:2141–2148, 2005.
561. Briani C, Zara G, Rondinone R, et al: Thalidomide neurotoxicity: Prospective study in 594. Fonseca R, Barlogie B, Bataille R, et al: Genetics and cytogenetics of multiple myeloma:
patients with lupus erythematosus. Neurology 62:2288–2290, 2004. A workshop report. Cancer Res 64:1546–1558, 2004.
562. Offidani M, Corvatta L, Marconi M, et al: Common and rare side-effects of low-dose 595. Haessler J, Shaughnessy JD, Jr., Zhan F, et al: Benefit of complete response in multiple
thalidomide in multiple myeloma: Focus on the dose-minimizing peripheral neuropa- myeloma limited to high-risk subgroup identified by gene expression profiling. Clin
thy. Eur J Haematol 72:403–409, 2004. Cancer Res 13:7073–7079, 2007.
563. Tosi P, Zamagni E, Cellini C, et al: Neurological toxicity of long-term (>1 yr) thalido- 596. Shaughnessy J, Tian E, Sawyer J, et al: High incidence of chromosome 13 deletion in
mide therapy in patients with multiple myeloma. Eur J Haematol 74:212–216, 2005. multiple myeloma detected by multiprobe interphase FISH. Blood 96:1505–1511, 2000.
564. Apfel SC, Zochodne DW: Thalidomide neuropathy: Too much or too long? Neurology 597. Plowright EE, Li Z, Bergsagel PL, et al: Ectopic expression of fibroblast growth factor
62:2158–2159, 2004. receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood 95:992–
565. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al: Osteonecrosis of the jaw in 998, 2000.
patients with multiple myeloma treated with bisphosphonates: Evidence of increased 598. Zhan F, Hardin J, Kordsmeier B, et al: Global gene expression profiling of multiple
risk after treatment with zoledronic acid. Haematologica 91:968–971, 2006. myeloma, monoclonal gammopathy of undetermined significance, and normal bone
566. Zervas K, Verrou E, Teleioudis Z, et al: Incidence, risk factors and management of marrow plasma cells. Blood 99:1745–1757, 2002.
osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience 599. Shaughnessy JD Jr, Zhan F, Burington BE, et al: A validated gene expression model of
in 303 patients. Br J Haematol 134:620–623, 2006. high-risk multiple myeloma is defined by deregulated expression of genes mapping to
567. Badros A, Weikel D, Salama A, et al: Osteonecrosis of the jaw in multiple myeloma chromosome 1. Blood 109:2276–2284, 2007.
patients: Clinical features and risk factors. J Clin Oncol 24:945–952, 2006. 600. Kuiper R, Broyl A, de Knegt Y, et al: A gene expression signature for high-risk multiple
568. Badros A, Terpos E, Katodritou E, et al: Natural history of osteonecrosis of the jaw in myeloma. Leukemia 26:2406–2413, 2012.
patients with multiple myeloma. J Clin Oncol 26:5904–5909, 2008. 601. Chauhan D, Auclair D, Robinson EK, et al: Identification of genes regulated by dex-
569. Clarke BM, Boyette J, Vural E, et al: Bisphosphonates and jaw osteonecrosis: The UAMS amethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 21:1346–
experience. Otolaryngol Head Neck Surg 136:396–400, 2007. 1358, 2002.
570. Sarasquete ME, Garcia-Sanz R, Marin L, et al: Bisphosphonate-related osteonecrosis of 602. Mitsiades N, Mitsiades CS, Poulaki V, et al: Molecular sequelae of proteasome inhibi-
the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple tion in human multiple myeloma cells. Proc Natl Acad Sci U S A 99:14374–14379, 2002.
myeloma: A genome-wide single nucleotide polymorphism analysis. Blood 112:2709– 603. Hideshima T, Podar K, Chauhan D, et al: P38 MAPK inhibition enhances PS-341
2712, 2008. (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23:8766–
571. Terpos E, Dimopoulos MA: Genetic predisposition for the development of ONJ. Blood 8776, 2004.
112:2596–2597, 2008. 604. Kyle RA, Garton JP: The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo
572. Montefusco V, Gay F, Spina F, et al: Antibiotic prophylaxis before dental procedures Clin Proc 62:719–731, 1987.
may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma 605. Avet-Loiseau H, Garand R, Lode L, et al: Translocation t(11;14)(q13;q32) is the hallmark
treated with bisphosphonates. Leuk Lymphoma 49:2156–2162, 2008. of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 101:1570–1571, 2003.
573. Khan AA, Sandor GK, Dore E, et al: Canadian consensus practice guidelines for bis- 606. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al: Waldenström’s macroglobu-
phosphonate associated osteonecrosis of the jaw. J Rheumatol 35:1391–1397, 2008. linemia: Clinical features, complications, and management. J Clin Oncol 18:214–226,
574. Blade J, Samson D, Reece D, et al: Criteria for evaluating disease response and progres- 2000.
sion in patients with multiple myeloma treated by high-dose therapy and haemopoietic 607. Dhodapkar MV, Jacobson JL, Gertz MA, et al: Prognostic factors and response to flu-
stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for darabine therapy in patients with Waldenström macroglobulinemia: Results of United
Blood and Marrow Transplant. Br J Haematol 102:1115–1123, 1998. States intergroup trial (Southwest Oncology Group S9003). Blood 98:41–48, 2001.
575. Martinez-Lopez J, Lahuerta JJ, Pepin F, et al: Prognostic value of deep sequenc- 608. Moulopoulos LA, Dimopoulos MA, Weber D, et al: Magnetic resonance imaging in the
ing method for minimal residual disease detection in multiple myeloma. Blood 123: staging of solitary plasmacytoma of bone. J Clin Oncol 11:1311–1315, 1993.
3073–3079, 2014. 609. Frassica DA, Frassica FJ, Schray MF, et al: Solitary plasmacytoma of bone: Mayo Clinic
576. Greipp PR: Prognosis in myeloma. Mayo Clin Proc 69:895–902, 1994. experience. Int J Radiat Oncol Biol Phys 16:43–48, 1989.
577. Bataille R, Jourdan M, Zhang XG, et al: Serum levels of interleukin 6, a potent myeloma 610. Knowling MA, Harwood AR, Bergsagel DE: Comparison of extramedullary plasmacyto-
cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest mas with solitary and multiple plasma cell tumors of bone. J Clin Oncol 1:255–262, 1983.
84:2008–2011, 1989. 611. Wiltshaw E: The natural history of extramedullary plasmacytoma and its relation to
578. Ludwig H, Nachbaur DM, Fritz E, et al: Interleukin-6 is a prognostic factor in multiple solitary myeloma of bone and myelomatosis. Medicine (Baltimore) 55:217–238, 1976.
myeloma. Blood 77:2794–2795, 1991. 612. Aviles A, Huerta J, Zepeda G, et al: Serum beta 2 microglobulin in solitary plasmocyto-
579. Bataille R, Boccadoro M, Klein B, et al: C-reactive protein and beta-2 microglobulin mata. Blood 76:1663, 1990.
produce a simple and powerful myeloma staging system. Blood 80:733–737, 1992. 613. Dimopoulos MA, Moulopoulos LA, Maniatis A, et al: Solitary plasmacytoma of bone
580. Seidel C, Borset M, Turesson I, et al: Elevated serum concentrations of hepatocyte and asymptomatic multiple myeloma. Blood 96:2037–2044, 2000.
growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. 614. Moulopoulos LA, Maris TG, Papanikolaou N, et al: Detection of malignant bone mar-
Blood 91:806–812, 1998. row involvement with dynamic contrast-enhanced magnetic resonance imaging. Ann
581. Seidel C, Sundan A, Hjorth M, et al: Serum syndecan-1: A new independent prognostic Oncol 14:152–158, 2003.
marker in multiple myeloma. Blood 95:388–392, 2000. 615. Durie BG, Waxman AD, D’Agnolo A, et al: Whole-body (18)F-FDG PET identifies
582. Dahl IM, Turesson I, Holmberg E, et al: Serum hyaluronan in patients with multiple high-risk myeloma. J Nucl Med 43:1457–1463, 2002.
myeloma: Correlation with survival and Ig concentration. Blood 93:4144–4148, 1999. 616. Hind CR, Gibson DG, Lavender JP, et al: Non-invasive demonstration of cardiac
583. Witzig TE, Gertz MA, Lust JA, et al: Peripheral blood monoclonal plasma cells as a involvement in acquired forms of systemic amyloidosis. Lancet 1:1417, 1984.
predictor of survival in patients with multiple myeloma. Blood 88:1780–1787, 1996. 617. Palladini G, Campana C, Klersy C, et al: Serum N-terminal pro-brain natriuretic pep-
584. Zhang H, Vakil V, Braunstein M, et al: Circulating endothelial progenitor cells in mul- tide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation
tiple myeloma: Implications and significance. Blood 105:3286–3294, 2005. 107:2440–2445, 2003.
585. Jakob C, Egerer K, Liebisch P, et al: Circulating proteasome levels are an independent 618. Libbey CA, Skinner M, Cohen AS: Use of abdominal fat tissue aspirate in the diagnosis
prognostic factor for survival in multiple myeloma. Blood 109:2100–2105, 2007. of systemic amyloidosis. Arch Intern Med 143:1549–1552, 1983.
586. Blade J, Kyle RA, Greipp PR: Presenting features and prognosis in 72 patients with mul- 619. Cooper JT, Bacon CP: A histochemical construct of the amyloid fibril in Amyloidosis
tiple myeloma who were younger than 40 years. Br J Haematol 93:345–351, 1996. edited by EARS, p 31. John Wright and Sons, Bristol, UK, 1983.
587. San Miguel JF, Garcia-Sanz R, Gonzalez M, et al: A new staging system for multiple 620. Dhodapkar MV, Jagannath S, Vesole D, et al: Treatment of AL-amyloidosis with dex-
myeloma based on the number of S-phase plasma cells. Blood 85:448–455, 1995. amethasone plus alpha interferon. Leuk Lymphoma 27:351–356, 1997.
588. Smadja NV, Bastard C, Brigaudeau C, et al: Hypodiploidy is a major prognostic factor 621. Palladini G, Perfetti V, Obici L, et al: Association of melphalan and high-dose dex-
in multiple myeloma. Blood 98:2229–2238, 2001. amethasone is effective and well tolerated in patients with AL (primary) amyloidosis
589. Le Baccon P, Leroux D, Dascalescu C, et al: Novel evidence of a role for chromosome who are ineligible for stem cell transplantation. Blood 103:2936–2938, 2004.
1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple 622. Dispenzieri A, Kyle RA, Lacy MQ, et al: Superior survival in primary systemic amyloi-
myeloma. Genes Chromosomes Cancer 32:250–264, 2001. dosis patients undergoing peripheral blood stem cell transplantation: A case-control
590. Sawyer JR, Tricot G, Mattox S, et al: Jumping translocations of chromosome 1q in study. Blood 103:3960–3963, 2004.
multiple myeloma: Evidence for a mechanism involving decondensation of pericentro- 623. Skinner M, Sanchorawala V, Seldin DC, et al: High-dose melphalan and autologous
meric heterochromatin. Blood 91:1732–1741, 1998. stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern
591. Sawyer JR, Tricot G, Lukacs JL, et al: Genomic instability in multiple myeloma: Evi- Med 140:85–93, 2004.
dence for jumping segmental duplications of chromosome arm 1q. Genes Chromosomes 624. Sanchorawala V, Wright DG, Rosenzweig M, et al: Lenalidomide and dexamethasone in
Cancer 42:95–106, 2005. the treatment of AL amyloidosis: Results of a phase 2 trial. Blood 109:492–496, 2007.

Kaushansky_chapter 107_p1733-1772.indd 1771 9/21/15 12:36 PM